<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102429">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01803360</url>
  </required_header>
  <id_info>
    <org_study_id>NERI-OA-2013</org_study_id>
    <nct_id>NCT01803360</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Neridronate to Treat Painful Osteoarthritis of the Knee With Bone Marrow Lesions.</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled Trial to Assess the Efficacy of Neridronate 100 mg -4 i.v. Infusions- in Patients With Painful Osteoarthritis of the Knee With Bone Marrow Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Gaetano Pini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Gaetano Pini</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether neridronate is effective in the treatment
      of pain related to bone marrow oedema in patients with osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>knee pain reduction</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>to assess the efficacy in terms of proportion of patients with a 50% reduction in pain intensity compared to baseline measured by VAS 100 mm scale recorded at the last visit (day 60)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone marrow lesions reduction</measure>
    <time_frame>60 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Neridronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution for infusion: 4 intravenous administrations in a course of 10 days treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neridronate</intervention_name>
    <description>Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment</description>
    <arm_group_label>Neridronate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of knee Osteoarthritis (ACR criteria)

          -  Radiographic diagnosis of knee Osteoarthritis (Kellgren/Lawrence scale &gt;=2)

          -  &gt;4 weeks but &lt;3 months pain, reported as &gt;30 mm on a 100 mm VAS scale

          -  bone marrow oedema of the affected knee on magnetic resonance

        Exclusion Criteria:

          -  inflammatory arthritis

          -  aseptic osteonecrosis of the knee

          -  previous or current treatment with Bisphosphonates

          -  serum calcium or creatinine abnormalities
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Massimo Varenna</last_name>
    <phone>00390258296897</phone>
    <email>varenna@gpini.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Ortopedico Gaetano Pini</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Varenna</last_name>
      <phone>00390258296897</phone>
      <email>varenna@gpini.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Varenna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 13, 2013</lastchanged_date>
  <firstreceived_date>March 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Gaetano Pini</investigator_affiliation>
    <investigator_full_name>Massimo Varenna</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
